- Prev Close
- 0.3061
- Today's Open
- 0.0400
- Day's Range
- 0.0330-0.0460
- Volume
- 9,347,039
- Dollar Volume
- $20417.39
- Avg Vol(5-day)
- 90,147
- Avg Vol(1-month)
- 145,622

http://www.nemusbioscience.com
Description
Nemus Bioscience, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and the commercialization of cannabinoid-based therapeutics through its partnership with the University of Mississippi (UM). It is UM's partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids. It is focused primarily on the development of early-stage cannabinoid product candidates, including NB1111, NB1222, NB3111 and NB2111. NB1111, a prodrug of Tetrahydrocannabinol (THC), is in the preclinical stage for the indication of glaucoma. NB1222 is a prodrug formulation of THC and is intended for systemic administration in the management of chemotherapy-induced nausea and vomiting (CINV). The NB2111 formulation technology is designed to permit better transmembrane translocation of cannabinoids. The NB3111 product candidate is in research stage for the indication of Methicillin-resistant Staphylococcus aureus (MRSA).
Company Address
CEO: Brian S. Murphy650 TOWN CENTER DRIVE SUITE 1770
COSTA MESA, CA 92626
United States
Have a suggestion?
Please Contact Us to let us know.
-
Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)
June 19, 2019
-
Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference
May 13, 2019
-
Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members
April 22, 2019
-
Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
April 8, 2019
-
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
April 1, 2019
-
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
March 25, 2019
-
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
March 18, 2019
-
Imaging3 Update on Execution of Letter of Intent for Reverse Acquisition by Grapefruit Boulevard Investments, Inc.
March 18, 2019
-
Nemus Bioscience to Present at 31st Annual ROTH Conference
March 13, 2019
-
Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
March 12, 2019
-
Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog
March 4, 2019
-
Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma
February 14, 2019
-
Nemus Bioscience to Present at BIO CEO & Investor Conference
February 7, 2019
-
Innovative Developments in Biotechnology set to Spur the Market Growth
January 23, 2019
-
Nemus Bioscience to Present at the NobleCon XV and 8th Annual Glaucoma 360 New Horizons Forum
January 23, 2019
-
Nemus Bioscience to Present at the 2nd Annual Sach’s Neuroscience Innovation Forum and Biotech Showcase 2019
January 3, 2019
-
Nemus Bioscience to Present at Investment and Scientific Conferences in December
November 29, 2018
-
Various Technological Advancements are set to Grow the Global Biotechnology Market
November 9, 2018
-
Nemus Bioscience to Present at BIO Investor Forum
October 15, 2018
-
Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares
October 8, 2018
-
NEMUS Bioscience to Present at The MicroCap Conference
September 26, 2018
-
NEMUS Bioscience to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 28, 2018
-
UPDATE: Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
August 1, 2018
-
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
July 20, 2018
-
Nemus Bioscience to Participate at the 8th Annual LD Micro Invitational
May 30, 2018
-
Nemus Bioscience Adds to Senior Leadership Team
May 7, 2018
-
Prominent Salk Institute Neuroscientist Joins Nemus Bioscience as Scientific Consultant
March 21, 2018
-
NEMUS Bioscience to Participate in Sachs BioCapital USA Forum at the New York Academy of Sciences
March 7, 2018
-
NEMUS Bioscience to Participate in BIO CEO Investor Conference to Provide Ophthalmology-Focused Pipeline Review
February 7, 2018
-
Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics
January 19, 2018
-
Nemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing
December 29, 2017
-
Imaging3 appoints John Hollister as CEO
December 20, 2017
-
Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee
November 9, 2017
-
NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings
November 6, 2017
-
Nemus Bioscience Announces $2,000,000 Series F Preferred Stock Financing
November 1, 2017
-
NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing
October 13, 2017
-
NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting
August 7, 2017
-
Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
August 2, 2017
-
NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting
July 17, 2017
-
NEMUS Bioscience Provides Update on Previously Announced $20 Million Schneider Financing
July 11, 2017
-
Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)
June 22, 2017
-
Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review 2017 – Key Companies Are Helsinn, Luxena Pharmaceuticals, Aphios, Nemus Bioscience & Tesaro – Research and Markets
May 23, 2017
-
Biotech Infusion Into Cannabis Product Development is Creating Strong Industry Growth Combination
May 11, 2017
-
Nemus Bioscience Announces $20 Million Series E Preferred Stock Financing
May 4, 2017
-
NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms
March 22, 2017
-
Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)
March 20, 2017
-
OTCQX And OTCQB Companies To Present At 2017 ROTH Conference
March 9, 2017
-
NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
March 3, 2017
-
Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules
December 20, 2016
-
Nemus Bioscience Announces Analog of Cannabidiol (CBD) Achieves Multi-Chamber Ocular Penetration in Animal Model Using Initial Ophthalmic Formulation
December 14, 2016
-
Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Intellectual Property Protection in the European Union (E.U.) and Australia Following Patents issued in the United States and Japan
December 12, 2016
-
Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy
November 16, 2016